bluebird bio Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc.

BLUE 4.970

0.0%

Jun 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	3/3/2014 1:30:57 PM
	of 163

Can the model T CARs progress from Fords to Ferraris? Here is a link to a Molecular Therapy editorial on the CAR-Ts move to the fast lane: nature.com Here are some growth pains discussed briefly: cytokine release syndrome upon infusion of CAR-T cells (note that corticosteroids to treat the syndrome are lympholytic) will CD-19 targeting successes be repeated with other tumor antigens? what about off target toxicities when the antigen is expressed in healthy tissues? can current generation CAR-Ts migrate to metastatic solid tumors? how about expansion of CAR-T production to deal with increasing patient numbers in clintrials?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next